Live In Play®
Updated: 09-Jul-24 06:34 ET
IMUX:  Immunic announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024  (1.16)
  • In the newly created role, Mr. Tardio will lead internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company's orally available nuclear receptor related 1 (Nurr1) activator. Jason will also work closely with Patrick Walsh, Chief Business Officer, to prepare the company for a range of potential partnership outcomes for vidofludimus calcium, as well as Immunic's other drug candidates.
  • Mr. Tardio most recently served as Chief Operating Officer of Ovid Therapeutics Inc. since June 2021, after joining the company as Chief Commercial Officer in November 2019.
  • "Jason's appointment reflects our commitment to both commercial and partnership preparedness and comes at a particularly important and exciting time with the upcoming read-out of our phase 2 CALLIPER trial in progressive MS expected in April 2025 and the completion of our twin phase 3 ENSURE trials in relapsing MS expected in the second quarter and the second half of 2026, respectively. We warmly welcome him to Immunic."
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.